Aptissen and KiOmed Pharma sign global agreement to expand access to KioMedinevsone
23 April 2025 Geneva, Switzerland & Liège, Belgium
Aptissen SA and KiOmed Pharma, two leaders in medical innovation and regenerative medicine, are thrilled to announce the signing of a landmark license and supply agreement for the global commercialization of KioMedine one—a pioneering single-injection treatment designed for patients suffering from refractory osteoarthritis (OA).
KioMedine one offers a unique, chitosan-based therapeutic approach, setting a new standard in OA care by delivering long-lasting relief in just one injection. This agreement marks a significant expansion of the companies’ previous collaboration, which was initially limited to Germany, Italy, and Poland. The new partnership paves the way for broader international access to this cutting-edge treatment and positions the companies to capture growing demand in the global osteoarthritis therapeutics market—projected to reach over $5 billion by 2030.
Aptissen, a Swiss-based medical device leader with a robust global presence in over 70 countries, brings a strong track record in ortho-biologics. With an extensive portfolio of musculoskeletal solutions, including the renowned Synolis product line, the company is committed to improving patient outcomes through next-generation medical technologies. “This agreement represents a major milestone in driving forward Aptissen’s mission,” said Silvia Scherer, CEO of Aptissen. “We are leveraging our proven global distribution network and commercial expertise to accelerate access to a product with high clinical and market potential, offering more treatment options with orthobiologic solutions for more physicians treating patients suffering from osteoarthritis.”
KiOmed Pharma, headquartered in Belgium, specializes in the development of advanced, chitosanbased products for rheumatology, dermatology, and ophthalmology. The company’s proprietary KiOmedine® technology platform is at the core of its innovative pipeline of therapeutic devices. “Our partnership with Aptissen allows KiOmed Pharma to rapidly scale the global impact of KioMedine one while focusing on innovation and evidence generation,” said Houtaï Choumane, CEO of KiOmed Pharma. “This agreement further validates our technology platform and ensures long-term value creation.”
Under the new agreement:
“This strategic partnership signifies more than just a commercial agreement—it’s a shared missionto transform the lives of millions living with osteoarthritis,” stated Gilles Bos and François Blondel,Founders and Chairmen of the Board of, respectively, Aptissen and KiOmed Pharma. “Together, weare accelerating access to a groundbreaking solution that delivers significant pain relief andrestores mobility for patients worldwide.”
